Shah RB - Search Results

1

A polycomb repression signature in metastatic prostate cancer predicts cancer outcome.

Yu J, Yu J, Rhodes DR, Tomlins SA, Cao X, Chen G, Mehra R, Wang X, Ghosh D, Shah RB, Varambally S, Pienta KJ, Chinnaiyan AM. Yu J, et al. Among authors: shah rb. Cancer Res. 2007 Nov 15;67(22):10657-63. doi: 10.1158/0008-5472.CAN-07-2498. Cancer Res. 2007. PMID: 18006806

2

Delineation of prognostic biomarkers in prostate cancer.

Dhanasekaran SM, Barrette TR, Ghosh D, Shah R, Varambally S, Kurachi K, Pienta KJ, Rubin MA, Chinnaiyan AM. Dhanasekaran SM, et al. Nature. 2001 Aug 23;412(6849):822-6. doi: 10.1038/35090585. Nature. 2001. PMID: 11518967 Free article.

3

Diagnostic usefulness of monoclonal antibody P504S in the workup of atypical prostatic glandular proliferations.

Kunju LP, Rubin MA, Chinnaiyan AM, Shah RB. Kunju LP, et al. Among authors: shah rb. Am J Clin Pathol. 2003 Nov;120(5):737-45. doi: 10.1309/3T3Y-0K0T-UMYH-3WY2. Am J Clin Pathol. 2003. PMID: 14608901

4

In vivo visualization of metastatic prostate cancer and quantitation of disease progression in immunocompromised mice.

Kalikin LM, Schneider A, Thakur MA, Fridman Y, Griffin LB, Dunn RL, Rosol TJ, Shah RB, Rehemtulla A, McCauley LK, Pienta KJ. Kalikin LM, et al. Among authors: shah rb. Cancer Biol Ther. 2003 Nov-Dec;2(6):656-60. Cancer Biol Ther. 2003. PMID: 14688471

5

Elevated alpha-methylacyl-CoA racemase enzymatic activity in prostate cancer.

Kumar-Sinha C, Shah RB, Laxman B, Tomlins SA, Harwood J, Schmitz W, Conzelmann E, Sanda MG, Wei JT, Rubin MA, Chinnaiyan AM. Kumar-Sinha C, et al. Among authors: shah rb. Am J Pathol. 2004 Mar;164(3):787-93. doi: 10.1016/s0002-9440(10)63167-7. Am J Pathol. 2004. PMID: 14982833 Free PMC article.

6

Androgen-independent prostate cancer is a heterogeneous group of diseases: lessons from a rapid autopsy program.

Shah RB, Mehra R, Chinnaiyan AM, Shen R, Ghosh D, Zhou M, Macvicar GR, Varambally S, Harwood J, Bismar TA, Kim R, Rubin MA, Pienta KJ. Shah RB, et al. Cancer Res. 2004 Dec 15;64(24):9209-16. doi: 10.1158/0008-5472.CAN-04-2442. Cancer Res. 2004. PMID: 15604294

7

Metastasis suppressor gene Raf kinase inhibitor protein (RKIP) is a novel prognostic marker in prostate cancer.

Fu Z, Kitagawa Y, Shen R, Shah R, Mehra R, Rhodes D, Keller PJ, Mizokami A, Dunn R, Chinnaiyan AM, Yao Z, Keller ET. Fu Z, et al. Prostate. 2006 Feb 15;66(3):248-56. doi: 10.1002/pros.20319. Prostate. 2006. PMID: 16175585 Free article.

8

Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer.

Tomlins SA, Rhodes DR, Perner S, Dhanasekaran SM, Mehra R, Sun XW, Varambally S, Cao X, Tchinda J, Kuefer R, Lee C, Montie JE, Shah RB, Pienta KJ, Rubin MA, Chinnaiyan AM. Tomlins SA, et al. Among authors: shah rb. Science. 2005 Oct 28;310(5748):644-8. doi: 10.1126/science.1117679. Science. 2005. PMID: 16254181

9

Integrative genomic and proteomic analysis of prostate cancer reveals signatures of metastatic progression.

Varambally S, Yu J, Laxman B, Rhodes DR, Mehra R, Tomlins SA, Shah RB, Chandran U, Monzon FA, Becich MJ, Wei JT, Pienta KJ, Ghosh D, Rubin MA, Chinnaiyan AM. Varambally S, et al. Among authors: shah rb. Cancer Cell. 2005 Nov;8(5):393-406. doi: 10.1016/j.ccr.2005.10.001. Cancer Cell. 2005. PMID: 16286247 Free article.

10

Comparison of monoclonal antibody (P504S) and polyclonal antibody to alpha methylacyl-CoA racemase (AMACR) in the work-up of prostate cancer.

Kunju LP, Chinnaiyan AM, Shah RB. Kunju LP, et al. Among authors: shah rb. Histopathology. 2005 Dec;47(6):587-96. doi: 10.1111/j.1365-2559.2005.02281.x. Histopathology. 2005. PMID: 16324196

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

222 results

Search Page

Filters